CONTEXT: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome, characterized by tumor secretion of fibroblast growth factor-23 (FGF23) causing hypophosphatemia due to renal phosphate wasting. TIO is usually caused by small, benign, difficult-to-localize, mesenchymal tumors. Although surgery with wide excision of tumor borders is considered the "gold standard" for definitive therapy, it can be associated with considerable morbidity depending on the location. To date, radiation therapy has not been considered as an effective treatment modality in TIO. OBJECTIVE: A 67-year-old female presented with multiple nontraumatic fractures, progressive bone pain, and muscle weakness for 4 years. She was found to have biochemical evidence of urinary phosphate wasting with low serum phosphorus, low-normal serum calcium, normal 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and high serum FGF23 levels. TIO was diagnosed. Selective venous sampling for FGF23 confirmed that a 1.7-cm left frontal mass, radiographically similar to a meningioma, was the causative tumor. She declined surgery due to fear of complications and instead underwent fractionated stereotactic radiotherapy for 6 weeks. RESULTS: In less than 4 years after radiation therapy, she was successfully weaned off phosphorus and calcitriol, starting from 2 g of oral phosphorus daily and 1 μg of calcitriol daily. Her symptoms have resolved, and she has not had any new fractures. CONCLUSIONS: Stereotactic radiotherapy was an effective treatment modality for TIO in our patient. Fractionated stereotactic radiation therapy represents an alternative to surgery for patients with TIO who are not surgical candidates or who decline surgery.
CONTEXT: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome, characterized by tumor secretion of fibroblast growth factor-23 (FGF23) causing hypophosphatemia due to renal phosphate wasting. TIO is usually caused by small, benign, difficult-to-localize, mesenchymal tumors. Although surgery with wide excision of tumor borders is considered the "gold standard" for definitive therapy, it can be associated with considerable morbidity depending on the location. To date, radiation therapy has not been considered as an effective treatment modality in TIO. OBJECTIVE: A 67-year-old female presented with multiple nontraumatic fractures, progressive bone pain, and muscle weakness for 4 years. She was found to have biochemical evidence of urinary phosphate wasting with low serum phosphorus, low-normal serum calcium, normal 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and high serum FGF23 levels. TIO was diagnosed. Selective venous sampling for FGF23 confirmed that a 1.7-cm left frontal mass, radiographically similar to a meningioma, was the causative tumor. She declined surgery due to fear of complications and instead underwent fractionated stereotactic radiotherapy for 6 weeks. RESULTS: In less than 4 years after radiation therapy, she was successfully weaned off phosphorus and calcitriol, starting from 2 g of oral phosphorus daily and 1 μg of calcitriol daily. Her symptoms have resolved, and she has not had any new fractures. CONCLUSIONS: Stereotactic radiotherapy was an effective treatment modality for TIO in our patient. Fractionated stereotactic radiation therapy represents an alternative to surgery for patients with TIO who are not surgical candidates or who decline surgery.
Authors: Suzanne M Jan de Beur; Elizabeth A Streeten; A Cahid Civelek; Edward F McCarthy; Liliana Uribe; Stephen J Marx; Olufunmilayo Onobrakpeya; Lawrence G Raisz; Nelson B Watts; Michael Sharon; Michael A Levine Journal: Lancet Date: 2002-03-02 Impact factor: 79.321
Authors: C L Maini; R Sciuto; A Tofani; A Ferraironi; C M Carapella; E Occhipinti; M Mottolese; M Crecco Journal: Nucl Med Commun Date: 1995-09 Impact factor: 1.690
Authors: Derek A Mathis; Edward J Stehel; Joseph E Beshay; Bruce E Mickey; Andrew L Folpe; Jack Raisanen Journal: J Neurosurg Date: 2013-01-25 Impact factor: 5.115
Authors: Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck Journal: Curr Rheumatol Rep Date: 2015-06 Impact factor: 4.592
Authors: Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins Journal: Calcif Tissue Int Date: 2020-06-05 Impact factor: 4.333
Authors: Kathryn Dahir; María Belén Zanchetta; Irinel Stanciu; Cemre Robinson; Janet Y Lee; Ruban Dhaliwal; Julia Charles; Roberto Civitelli; Mary Scott Roberts; Stan Krolczyk; Thomas Weber Journal: J Endocr Soc Date: 2021-06-02
Authors: Anke H Hautmann; Josef Schroeder; Peter Wild; Matthias G Hautmann; Elisabeth Huber; Patrick Hoffstetter; Martin Fleck; Christiane Girlich Journal: Case Rep Endocrinol Date: 2014-08-24